Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy

Trial Profile

QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs YE-NEO-001 (Primary) ; Aldoxorubicin; ALT 803; Avelumab; Bevacizumab; Brachyury peptide vaccine; Capecitabine; CST 101; Cyclophosphamide; ETBX 011; ETBX 021; ETBX-051; ETBX-061; Fluorouracil; Folinic acid; GI 4000; GI 6207; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 08 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 19 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top